CurrentNeighborhood Health Plan of Rhode IslandPolicy 1486-A

Rosacea prescription drug authorization

Covers prior authorization and approval criteria for prescription topical and oral medications indicated for inflammatory lesions and/or persistent erythema of rosacea for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyRosacea prescription drug authorization

Policy CodePolicy 1486-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain prior authorization and document a rosacea diagnosis with evidence of symptom reduction from baseline.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7drugs referenced

Emrosi, Finacea, Mirvaso, Noritate, Rhofade, Soolantranamed products

4 moinitial DOA

12–36 mocontinuation DOA

Coverage Criteria

General authorization criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Authorization Rules

Prior Authorization

Prior Authorization Required

Prior authorization required. Approval is contingent on a documented diagnosis of rosacea and evidence the patient has experienced a reduction in rosacea symptoms from baseline (for example, fewer inflammatory papules or pustules, or reduced facial erythema).

Prior authorization required for Emrosi (oral minocycline ER).
Authorization may be granted when rosacea diagnosis and symptom reduction from baseline are documented.
Initial approval durations: Emrosi — 4 months; Continuation — 12 months.

Note

Emrosi-specific Indication and Use Limits

Emrosi (oral minocycline ER) is indicated for the treatment of inflammatory lesions of rosacea in adults. Use should be limited to the indicated population and not for treatment or prevention of infections; to reduce development of resistant bacteria, use Emrosi only as indicated.

Indication: inflammatory lesions of rosacea in adults.
Limitation of use: not evaluated for treatment or prevention of infections; use only as indicated to reduce resistance.

Documentation Required

Documentation Required for Authorization

Document the diagnosis of rosacea in the medical record and provide objective evidence that the patient has experienced a reduction in rosacea symptoms from baseline (e.g., decrease in inflammatory papules/pustules or improvement in facial erythema). Maintain documentation to support both initial and continuation authorization requests.

Documented diagnosis of rosacea required.
Evidence of symptom reduction from baseline (examples: fewer papules/pustules, reduced erythema).
Retain documentation for initial and continuation approvals.

Prior Authorization

Authorization Conditions and Duration

Authorization is granted when the patient has a diagnosis of rosacea and documentation shows a reduction in rosacea symptoms from baseline; follow the listed durations of approval for initial and continuation therapy.

Authorization condition: rosacea diagnosis + documented symptom reduction from baseline.
Duration of approval: Emrosi — Initial 4 months; Continuation 12 months.

Definitions

inv-08: Inflammatory lesions of rosacea

DefinitionInflammatory lesions of rosacea are papules and pustules associated with rosacea.

Indicated oral agentEmrosi (minocycline hydrochloride extended-release) — indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.

Topical azelaic acid optionFinacea Gel, 15% — indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Topical ivermectin optionSoolantra cream — indicated for the treatment of inflammatory lesions of rosacea.

inv-09: Persistent erythema of rosacea

DefinitionPersistent erythema of rosacea is nontransient facial redness associated with rosacea.

Topical alpha-adrenergic agonistMirvaso (brimonidine) topical gel, 0.33% — indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years or older.

Topical alpha-adrenergic agonist alternativeRhofade (oxymetazoline hydrochloride) cream, 1% — indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

Background

Rosacea commonly presents with inflammatory lesions (papules and pustules) and/or persistent facial erythema. Topical agents differ by target: azelaic acid, metronidazole, and ivermectin formulations are directed at the inflammatory papules and pustules, while alpha-adrenergic agonists and vasoconstrictors such as brimonidine and oxymetazoline are used to reduce persistent erythema. Oral extended-release minocycline (Emrosi) is specifically indicated for the inflammatory lesion component in adults.